CBIH Cannabis Bioscience International Holdings, Inc.
Services-Commercial Physical & Biological Research · OTC · SEC CIK 1411057 · Fiscal year ends 05/31
Financial factors as of 2026-02-28 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-64.1%
TTM net income YoY-8.9%
TTM EPS YoY-461.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin78.8%
Operating margin-322.6%
Net margin-416.8%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-6,272.5%
ROIC (approx.)—
Asset turnover15.05x
Leverage & solvency
Liabilities / assets95,121.4%
Debt / equity—
Current ratio0.00x
Interest coverage-2.68x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-3,008.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-02-28 | 2026Q22025-11-30 | 2026Q12025-08-31 | 2025Q4*2025-05-31 | 2025Q32025-02-28 | 2025Q22024-11-30 | 2025Q12024-08-31 | 2024Q4*2024-05-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11,205 | $53,266 | $24,200 | $34,956 | $14,931 | $74,248 | $178,887 | $75,862 |
| Cost of revenue | $3,045 | $10,500 | $8,143 | $4,545 | $19,396 | $7,803 | $8,362 | $9,878 |
| Gross profit | $8,160 | $42,766 | $16,057 | $30,411 | -$4,465 | $66,445 | $170,525 | $65,984 |
| SG&A expense | $26,828 | $30,972 | $23,308 | -$49,690 | $50,172 | $40,128 | $61,296 | $9,747 |
| Operating income | -$93,259 | -$95,877 | -$74,784 | -$134,900 | -$129,234 | -$59,627 | -$97,604 | -$29,634 |
| Interest expense | $10,776 | $17,860 | $17,368 | $102,749 | $22,473 | $8,701 | $2,339 | $95,302 |
| Net income | -$103,933 | -$116,966 | -$82,645 | -$211,744 | -$181,243 | -$79,528 | -$76,305 | -$135,935 |
| EPS (basic) | -0.00 | -0.00 | -0.00 | — | -0.00 | -0.00 | -0.00 | — |
| EPS (diluted) | -0.00 | -0.00 | -0.00 | — | -0.00 | -0.00 | -0.00 | — |
| Weighted avg. shares (diluted) | 11.63B | 11.63B | 11.63B | — | 10.73B | 10.50B | 10.46B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $90 | $132 | $223 | $12,952 | $548 | $1,002 | $969 | $755 |
| Receivables | $1,266 | $21,811 | $8,966 | $6,380 | $2,640 | — | $17,176 | $20,139 |
| Current assets | $1,544 | $22,131 | $18,942 | $29,085 | $3,786 | — | $18,743 | $21,492 |
| Total assets | $1,544 | $22,131 | $18,942 | $31,880 | $14,886 | — | $46,280 | $57,162 |
| Current liabilities | $1.22M | $1.14M | $1.02M | $945,963 | $970,058 | — | $852,097 | $881,909 |
| Short-term debt | $14,592 | $14,952 | $14,952 | $14,592 | $14,592 | — | $7,054 | $7,054 |
| Long-term debt | $249,500 | $249,500 | $249,500 | $249,500 | $249,501 | — | $249,500 | $249,361 |
| Total debt | $264,092 | $264,452 | $264,452 | $264,092 | $264,093 | — | $256,554 | $256,415 |
| Total liabilities | $1.47M | $1.39M | $1.27M | $1.20M | $1.24M | — | $1.10M | $1.14M |
| Shareholders' equity | -$1.47M | -$1.36M | -$1.25M | -$1.16M | -$1.23M | -$1.13M | -$1.06M | -$1.08M |
| Net debt | $264,002 | $264,320 | $264,229 | $251,140 | $263,545 | — | $255,585 | $255,660 |
| Shares outstanding | 11.63B | 11.63B | 11.63B | 11.63B | 10.93B | — | 10.56B | 10.43B |
| Cash flow statement | ||||||||
| Operating cash flow | -$14,597 | -$5,493 | -$103,712 | -$144,312 | -$82,812 | -$72,090 | -$30,413 | -$174,439 |
| Financing cash flow | — | — | — | $156,716 | — | — | $30,627 | $174,400 |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.